The Promise of GLP-1 Drugs: More Than Just Diabetes Management When GLP-1 (Glucagon-Like Peptide-1) receptor agonists first hit the market, they were hailed as a breakthrough in type 2 diabetes
While GLP-1 medications were originally developed for Type II diabetes management, they are now widely used for metabolic health and weight management in non-diabetic patients who have obesity, insulin resistance, or weight loss resistance
Omzo's brand materials describe tirzepatide as offering "dual-hormone support that targets appetite, blood sugar, and metabolism for deeper, sustained progress." Clinical trials of tirzepatide (the active ingredient in Zepbound and Mounjaro) have shown substantial weight loss outcomes in studied populations, and some trials have shown greater average weight reduction with tirzepatide compared to semaglutide in head-to-head comparisons - though individual responses vary and neither medication is appropriate for all patients
Meeting highlights: PRAC 2326 October 2023 GLP-1 receptor agonists and thyroid cancer
If you'd like to see videos before anyone else, support this show directly, there's a link down in the description where you can learn more, and I'll see you in the next video
A few small animal studies show these bacteria could slightly increase GLP-1 levels